

Erratum

Interleukin-17 promotes the development of ovarian cancer through upregulation of MTA1 expression: Am J Cancer Res. 2022; 12(12): 5646-5656

Na Guo^{1,2}, Jiawen Zhang^{1,2}

¹The Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu 610041, Sichuan, China; ²Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, Sichuan, China

Received January 30, 2023; Accepted February 8, 2023; Epub February 15, 2023; Published February 28, 2023

In this article, we found that some word expressions were wrong and inappropriate. We apologize for any inconvenience or confusion caused by these errors. The correct version is shown as Erratum Table below.

China Second University Hospital of Sichuan University, No. 20 The Third Section of South Renmin Road, Chengdu 610041, Sichuan, China. Tel: +86-28-85502391; Fax: +86-28-85559065; E-mail: guona507@aliyun.com

Address correspondence to: Dr. Jiawen Zhang, The Department of Obstetrics and Gynecology, West

Interleukin-17 promotes the development of ovarian cancer

| Before modification | After modification | Page |
|--|--|-----------|
| Figure 3. IL-17 promotes ovarian cancer apoptosis. A. In nude mice, the tunel test was performed, and positive cells increased in the Secukinumab and Pterostilbene groups; B. The tumor volume increased in the Secukinumab and Pterostilbene groups compared with the control group after the first week of injection; C. Apoptotic rates decreased in the IL-17 group, * $P < 0.05$. | Figure 3. IL-17 inhibits ovarian cancer apoptosis. A. In nude mice, the tunel test was performed, and positive cells increased in the Secukinumab and Pterostilbene groups; B. The tumor volume decreased in the Secukinumab and Pterostilbene groups compared with the control group after the first week of injection; C. Apoptotic rates decreased in the IL-17 group, * $P < 0.05$. | Page 5652 |
| IL-17 promotes apoptosis of ovarian cancer cells | IL-17 inhibits apoptosis of ovarian cancer cells | Page 5650 |
| To further understand the role of IL-17 in promoting ovarian cancer cell apoptosis in ovarian cancer cells | To further understand the role of IL-17 in inhibiting ovarian cancer cell apoptosis in ovarian cancer cells | Page 5650 |
| We found that the tumor volume increased in the Secukinumab and Pterostilbene groups compared with the control group after the first week of injection | We found that the tumor volume decreased in the Secukinumab and Pterostilbene groups compared with the control group after the first week of injection | Page 5650 |
| we found that IL-17-induced migration, invasion, and apoptosis of CAOV-3 and OVCAR-3 cells, and the tumor volume increased in the Secukinumab and Pterostilbene groups compared with the control group after the first week of injection | we found that IL-17-induced migration, invasion, and inhibited apoptosis of CAOV-3 and OVCAR-3 cells, and the tumor volume decreased in the Secukinumab and Pterostilbene groups compared with the control group after the first week of injection | Page 5655 |